The major histocompatibility complex (MHC) class I and II glycoproteins play essential roles in the homeostatic function of distinguishing non-self (foreign) material from self. The MHC class I molecules bind endogenously processed viral peptides for recognition by cytotoxic T lymphocytes (CTL), a process that is essential for overcoming both persistent and acute viral infections. However, such a normal immune repertoire must be carefully honed to recognize those peptides required to achieve immunologic protection while avoiding recognition of peptides that mimic self-antigens.
Progress has been made in understanding several rules of antigen presentation, largely by complementing biologic with physiochemical and structural studies. Studies of several endogenously processed viral peptides (5, 9, 20, 21, 27, 28) indicate that they display MHC allele-specific motifs with lengths of 8 to 11 amino acids. Crystallographic studies of MHC molecules in complexes with viral peptides show that the molecules' flexible conformations allow these 8-to 11-amino-acid peptides to bind into the MHC groove once their anchoring residues are fixed (1, 7, 15, 32) .
Lymphocytic choriomeningitis virus (LCMV) is a negativestrand RNA virus with an ambisense coding strategy (16, 24) . The viral genome consists of two segments, a large (L) and a small (S) RNA of 7.2 and 3.4 kb, respectively. The L RNA encodes a large (L) protein (ϳ200 kDa) that is the viral polymerase and a Z protein (10 to 12 kDa) that contains a cysteine 2 -histidine 2 zinc finger motif. The S segment encodes three major structural proteins, the nucleocapsid protein (NP; 63 kDa) and two surface glycoproteins, GP1 (43 kDa) and GP2 (36 kDa), that derive from a common precursor polypeptide. We have used genetic reassortants of different LCMV strains and vaccinia virus (VV) recombinants to express GP, NP, Z (14, 30) , and L (4a) proteins. Studies have indicated that H-2 b mice generate CTL to the GP and NP proteins encoded by the S RNA and not to proteins encoded by the L RNA (22, 23, 29) . Finer analysis with GP and NP deletion mutants expressed by VV and overlapping synthesized peptides revealed that three peptide sequences, two for GP (amino acids [aa] 33 to 41, KAVYNFATC ([GP1] and aa 276 to 286, SGVENPGGYCL [GP2]) and one for NP (NP aa 396 to 404, FQPQNGQFI), bind to H-2 b MHC class I molecules and are recognized by CTL (9, 12, 20, 29, 31 We used this knowledge of CTL epitopes (peptide sequences) and CTL clones that recognized GP1, GP2, or NP to generate CTL escape virus variants with mutations in each of these peptides (14) . Here we extend those data by mutating the GP1 and GP2 peptides in a single variant virus (GPV) or in all three CTL peptide sequences, GP1, GP2, and NP (GPVϩ NPV). Computer analysis revealed 11 additional GP and 20 NP D b -restricted motifs, of which only 2 GP and 1 NP peptide bound to D b with affinities similar to those of known GP1, GP2, and NP CTL peptide sequences. This result indicated that prediction of potential CTL epitopes for vaccine or diagnostic purposes based only on primary sequence analysis for MHC class I allele specific anchoring motif is of limited usefulness and that knowledge and an understanding of structural constraints on peptide primary structure and conformation are needed for prediction to be meaningful. Second, we showed that inoculation of GPV CTL escape variants or GPVϩNPV escape variants failed to generate CTL responses to the newly predicted three D b motif peptides in GP and NP proteins that displayed good MHC D b binding affinity. However, a novel CD8
ϩ CTL response to a non-GP, non-NP protein was generated. These observations indicate that there is a rigid control that limits the number of peptides from a viral protein that can be utilized for CTL recognition but that within that control, the immune system has the flexibility to generate a CTL response to a novel protein.
MATERIALS AND METHODS

Mouse strains and cell lines. C57BL/6 (H-
bb ), and CD4 (H-2 bb ) gene knockout mice were obtained from the breeding colony at the Scripps Research Institute and used when 6 to 10 weeks of age.
, and BHK cell lines were maintained in culture as described before (9, 14) .
Viruses and generation of double and triple viral variants. The origin, cloning, sequencing, and plaque purification of LCMV ARM clone (Cl) 53b wild-type (wt) virus have been described elsewhere (4, 9, 20, 26) . Infection by LCMV was quantitated by counting PFU on Vero cells (4) and assessing expression of viral antigen, GP, or NP with specific mouse monoclonal antibodies and a fluorescein isothiocyanate-labeled antibody to mouse immunoglobulin G (IgG) (3, 14) . Generation of single CTL escape virus variants has been described elsewhere (14) , and the making of double and triple CTL escape variants is outlined below. Briefly, a CTL escape variant with a mutation in the GP1 CTL epitope GP aa 33 to 41 was used to infect (at a multiplicity of infection [MOI] of 0.001) rapidly growing H-2 b MC57 cells. After a 1-h incubation at 37ЊC, cells were washed three times, cultured for an additional hour at 37ЊC, and incubated with D b -restricted CTL clones that recognized GP aa 276 to 286 (50 parts CTL to 1 part infected cells) for an additional 48 h. Viruses were then harvested, and plaques were picked and tested for their ability to infect MC57 cells without recognition by GP1 and GP2 CTL clones. Two rounds of selection were required prior to development of GP1 and GP2 double escape variants (referred to as GPV).
To select triple CTL escape variants, the procedure was repeated as described above except that GPV was used to infect MC57 cells and selection was done with NP CTL that recognized NP aa 396 to 404. The resultant triple variants are referred to as GPVϩNPV, and an additional two passages were required for their selection. Several GPV and GPVϩNPV were obtained by this protocol and passaged in BHK or MC57 cells to obtain master seed cultures. Such passaged viruses maintained their phenotypes, as confirmed when neither GP1 nor GP2 CTL recognized GPV-infected 51 Cr-labeled H-2 b targets as foreign but CTL to NP did so. Furthermore, inoculation of H-2 b cells with the triple mutant GPVϩNPV resulted in permissive viral infection and expression of viral protein on the cell surface, but no lysis by CTL to GP1, GP2, or NP epitopes occurred.
Details concerning the construction and use of recombinant VV expressing full-length NP of LCMV ARM (VV NP), GP (VV GP), the two GP epitopes (VV GP1 and VV GP2), Z, and L (4a) have been published elsewhere (13, 14, 19, 29) .
RNA sequencing. RNA sequencing was performed as described before (14, 25) . Peptide synthesis and D b binding assays. Peptides were synthesized by the solid-phase method on an Applied Biosystems 430A automated peptide synthesizer with either t-BOC or FMOC chemistries (9) . Peptides were purified by high-pressure liquid chromatography (HPLC) on reverse-phase columns (Vydac C18 and a Waters apparatus), and the purity was Ͼ98%. The identity of the purified peptide was established by fast atom bombardment mass spectrum analysis. Peptide stock solutions were made at a peptide concentration of 3 ϫ 10 Ϫ3 M in 5% dimethyl sulfoxide and 1% bovine serum albumin in phosphatebuffered saline (BSA-PBS) and then stored at Ϫ20ЊC.
Competition CTL generation and detection. Primary LCMV-specific CTL were generated by priming mice intraperitoneally (i.p.) with 10 5 PFU of LCMV ARM wt, GPV, or GPVϩNPV. Spleens from these mice were removed 7 days after inoculation, and single-cell suspensions of splenocytes (free from erythrocytes) were prepared in complete RPMI 1640 medium. These cells were then tested for the ability to lyse virus-infected or peptide-coated targets as described before (14, 19, 20, 29) . Secondary cytotoxic effector cells were generated by immunizing mice i.p. with 10 5 PFU of LCMV ARM wt, GPV, or GPVϩNPV. Six to 7 weeks later, spleens were removed, freed of erythrocytes, and restimulated in vitro with syngeneic LCMV ARM-, GPV-, or GPVϩNPV-infected peritoneal exudate macrophages (12, 14, 20) . CTL clones were generated from such secondary effectors by limiting dilutions and then recloned three times.
A standard 5-to 6-h 51 Cr release assay (14, 19, 20, 29) was used to measure CTL activity. Target cells were infected with LCMV ARM wt, GPV, or GPVϩNPV at an MOI of 1 48 h before the assay or with recombinant VV at an MOI of 3 16 h before the assay. The percent specific lysis was calculated as 100 ϫ [(cpm released by CTL Ϫ cpm of spontaneous release)/(cpm of total release Ϫ cpm of spontaneous release)].
RESULTS
Generation of GPV and GPV؉NPV CTL escape variants and biochemical characterization of their mutated sequences.
Following the protocol outlined, CTL escape variants to the two known D b -restricted GP peptide epitopes and also the GP and NP D b -restricted peptides (GP aa 33 to 41, GP aa 276 to 286, and NP aa 396 to 404) were generated. GPV replicated and expressed viral antigens in and on the surfaces of MC57 H-2 b target cells and produced 5 ϫ 10 6 PFU of infectious progeny per ml at 48 h postinfection. As shown in Table 1 , CTL clones to GP1 and GP2 failed to lyse GPV-infected H-2 b cells. As expected, bulk spleen CTL obtained 7 days after inoculation of H-2 b mice with LCMV wt recognized syngeneic target cells that expressed LCMV ARM GP aa 33 to 41, GP aa 276 to 286, and NP aa 396 to 404 and also recognized GPVinfected targets, since the NP aa 396 to 404 sequence was not mutated. This was documented when the NP CTL clone recognized NP aa 396 to 404 in syngeneic target cells infected by GPV. RNA sequence analysis of the GPV revealed mutations from F to L at aa 38 and from V to A at aa 278 in the viral glycoproteins.
H-2 b target cells infected with the GPVϩNPV mutant escaped lysis by day 7 primary CTL generated in H-2 b mice (Table 1) . GPVϩNPV replicated in H-2 b target cells and produced 2 ϫ 10 7 PFU of virus per ml of culture fluid 48 h after inoculation (MOI of 3). By contrast, LCMV wt at a corresponding time infected similar numbers of cells and synthesized 6 ϫ 10 7 PFU of virus per ml. The GPVϩNPV variant also infected H-2 d targets and primed them for killing by H-2 d -restricted CTL; these CTL recognized NP aa 118 to 127 (19, 30) . Sequencing of viral RNA indicated single point mutations from F to L at aa 38 for GP1, from V to A at aa 278 for GP2, and from F to L at aa 403 for NP. (Fig. 1) . By contrast, all other peptides were several-to 2,000-fold lower in D b binding affinity (11) . Table 2 shows that the secondary CTL and CTL clones generated in this way were all restricted to LCMV NP determinants and did not recognize syngeneic target cells expressing LCMV GP. -restricted CTL, but this response was not directed against GP or NP determinants and was less intense than that generated by wt virus. Use of ␤2M and CD4 knockout mice as well as antibody and complement to deplete CD4 or CD8 lymphocyte populations showed that the CTL response generated following inoculation of GPVϩNPV virus was mediated by CD8 ϩ CD4 Ϫ T lymphocytes. As expected, GPVϩNPV inoculated into H-2 d mice generated a response to LCMV NP aa 118 to 127. With VV recombinants expressing LCMV GP, NP, Z, or L, this CD8 ϩ CD4 Ϫ response in C57BL/6 H-2 b mice follow- (Table 4) . Thus, over several independent experiments, the specific 51
Cr release from H-2 b targets expressing GP, NP, or Z was Ͻ5% (10 mice studied), and that from targets expressing the L protein was 16% Ϯ 3% (8 mice studied; CTL used at effector-to-target cell at [E:T] ratios of 50:1). Despite numerous attempts, we have not yet been able to clone L-specific CTL. Interestingly, in none of more than 10 individual C57BL/6 H-2 b mice inoculated with LCMV wt was a CTL response generated to either the Z or L protein.
DISCUSSION
This study establishes three points. First, the CTL repertoire is limited. As recorded here, even if all the known GP or NP -restricted CTL epitopes (GPVϩNPV) were generated as depicted in Fig. 1 and detailed in Materials and Methods. These CTL escape variants and LCMV ARM wt were used to infect H-2 b (MC57) or H-2 d (BALB/c17) targets at an MOI of 1. VV recombinants expressing LCMV ARM wt NP, GP, or two GP epitopes, GP1 and GP2, were used at an MOI of 3. Forty-eight hours after infection with LCMV or the variants and 16 h after infection with VV recombinants, cells were labeled with 51 Cr and incubated with either LCMV-specific CTL clones or bulk splenic CTL obtained 7 days after a primary inoculation of 10 5 PFU of LCMV ARM wt virus i.p. E:T ratios were 5:1 and 2.5:1 for clones and 50:1 and 25:1 for primary CTL, with data for the 5:1 and 50:1 ratios shown. After 5 to 6 h, 51 Cr cpm released in the fluid phase were quantitated, and the specific 51 Cr release was calculated as described in Materials and Methods. Values represent the mean for three independent samples. A value of Ն11% was considered significant. Variance was Ͻ10%. The experiment was repeated multiple times, including when virus was harvested for RNA sequencing.
b ND, not determined. a Eight-to 10-week-old C57BL/6 or BALB mice were inoculated i.p. with 10 5 PFU of LCMV ARM wt or GPV. Seven days later, splenic CTL (primary response) were obtained and used in a 5-to 6-h 51 Cr release assay as described in Materials and Methods and Table 1 , footnote a. The same stock of GPV was used to generate CTL or infected cells as targets for CTL recognition. Other mice were killed 45 to 60 days after the primary inoculation; secondary CTL were obtained and cloned as described in Materials and Methods and references 12, 20, and 31. Infection of various targets was done as described in Table 1 , footnote a. Values represent the mean from three independent samples, and the variance was Ͻ10%.
b ND, not determined.
peptides on a viral protein that serve as epitopes for CTL recognition are mutated and rendered ineffective, new GP or NP peptide epitopes do not take their place. This indicates that there is a strict regulation and limit on peptides usable for such purposes. Such limitation occurs even though peptides have the appropriate anchor residues necessary for binding to the MHC groove to form a complex for recognition by CTL. This limitation in the number of peptides that can serve as CTL epitopes may confer a selective advantage by regulating the number of peptides available as mimicking peptides for autoreactive T cells and thereby reducing the likelihood of autoimmune disease (17) . The second point noted in this study is that despite a wealth of peptides within LCMV GP and NP molecules that contain the correct D b binding motif, as determined by analysis of the linear sequence, this predictive approach is of limited value. First, peptides so selected may not bind with sufficient affinity to MHC class I molecules, and second, the few that bind may not be able to function as a recognition unit for CTL. Thus, of the 34 LCMV ARM GP and NP peptides displaying the D b motif, only 6 (18%) bound at high affinity to MHC class I molecules, and of these, only 3 (8%) eventually functioned as an epitope for CTL recognition. It is likely that other factors, such as knowledge of the secondary and/or tertiary structure and appropriate folding for a conformationally active peptide, are required before one can predict which viral peptides should be included in a vaccine to ensure T-cell immunity. CTL generated against LCMV ARM wt, GPV, and GPVϩ NPV fail to recognize the three peptides, LCMV residues GP aa 92 to 101, GP aa 392 to 400, and NP aa 165 to 175, that bind Cr release from targets infected or coated with:
a Inoculation of LCMV variants in which the known GP CTL peptide epitopes (GPV) or GP and NP epitopes (GPVϩNPV) are mutated does not lead to the generation of new H- (Fig. 3 and Tables 2 to 4) . One likely explanation is that during LCMV infection, antigen-presenting cells do not process GP aa 92 to 101, GP 392 to 400, or NP aa 165 to 175 because their flanking sequences are not appropriate for cytosolic cleavage. Alternatively, their flanking sequences may not allow transfer by the transporter-associated protein (TAP) to the endoplasmic reticulum. These possibilities are currently under evaluation.
Mutations of F to L at GP aa 38 and V to A at GP aa 278 were generated in GPV and of F to L at GP aa 38, V to A at GP aa 278, and at NP aa 403 were generated in GPVϩNPV under CTL selective pressure. Interestingly, these mutations are found to occur at residues that point out and away from the MHC groove (14) when they are compared with the known structure of the influenza virus NP D b -restricted peptide AS-NENMETM (aa 366 to 374) using the coordinates from the recently solved crystallographic structure of D b (32) . The third point that this study establishes is that a CTL response can still be mounted to CTL escape variants in which all of the only three known CTL epitopes (9, 12, 20, 23, 31) were mutated. The CTL response generated, although definite, was lower than that observed with LCMV ARM wt or the CTL variant in which two of the three known CTL epitopes were mutated. The response was mediated by CD8 ϩ lymphocytes, as H-2 b mice genetically deficient in CD8 cells were unable to mount a measurable CTL response, while mice deficient in CD4 lymphocytes were. Elsewhere, we noted that the CTL response generated was sufficient to clear virus and control infection, although with slower kinetics (14a).
Thus, although there is a strict hierarchical control for the number of peptide sequences within a viral protein that can be utilized as a CTL epitope, there are evidently peptides in proteins that ordinarily do not function as CTL epitopes that can be utilized when known peptide sequences are rendered nonfunctional by mutation. In our studies, mutation of the known GP1, GP2, and NP CTL epitopes did not result in the appearance of new GP or NP epitopes. However, a CTL response was generated against a novel epitope(s) of the L protein encoded by the L RNA of the virus. Our attempts to clone L-specific CTL have not yet succeeded, presumably because of low L protein expression in infected cells (6, 8, 26) . The portion of L peptide recognized is not yet known, and therefore L peptide cannot be used to amplify the system, and such CTL are likely of low affinity (27a). Interestingly, a CTL response against the L protein was not observed in H-2 b mice inoculated with the nonmutated wt virus. This may be due to the low levels of L protein transcription and translation made during infection in vitro (6, 8, 26) and in vivo (2, 6, 18) , compared with production of the GP and NP, or the possible low affinity of the L protein peptide(s) that binds to the H-2 b MHC class I molecule.
This flexibility of the immune system for generating CTLs to a protein not ordinarily utilized as a recognition molecule for CTL, together with the observation of the low frequency of obtaining mutations for all functional epitopes in one virus (i.e., Ͻ2 ϫ 10 Ϫ8 probability for random mutation to involve the three authentic D b -restricted peptides for LCMV ARM wt) (14) and the heterogeneity of MHC glycoproteins in an outbred population like humans, makes it unlikely that biologically functional CTL escape variants play a significant role in the establishment of persistent infection.
